Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Exenatide.

But clinical evidence is limited.

The researchers assessed the effects of these antihyperglycemic agents on bone metabolism in patients with newly diagnosed type 2 diabetes.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

Sixty-two newly diagnosed and drug-naïve patients with type 2 diabetes were randomized to exenatide (EXE, n = 20), mixed protamine zinc recombinant human insulin lispro injection (25R; INS, n = 21) or pioglitazone (PIO, n = 21) group for a 24-week treatment.

How the Study Was Run

In design terms this was a randomized and parallel-group study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Exenatide group and the comparison group ran side by side rather than switching.

The methods mention a period of 24 weeks.

The present study was a two-center, randomized, parallel-group clinical trial.

Glycosylated hemoglobin A1c (HbA1c), body weight, body mineral density (BMD) and fasting serum concentration of bone turnover markers including osteocalcin (OC), C-telopeptide of type I collagen (CTX) and tartrate-resistant alkaline phosphatase 5b (TRAcP5b) were assessed at baseline and week 24.

What Was Measured

Topics PubMed links to this paper include Bone Density, Bone and Bones, Collagen Type I, Diabetes Mellitus, Type 2, Exenatide, Glycated Hemoglobin and Hypoglycemic Agents.

Author keywords: Bone mineral density, Bone turnover marker, Insulin, Newly diagnosed type 2 diabetes and Pioglitazone.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Exenatide over 24 weeks.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Acta diabetologica), a journal based in Germany.

More context: the Exenatide compound page, all human trials.